Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) is characterized by cytopenias, marrow fibrosis, constitutional symptoms, extramedullary hematopoiesis, splenomegaly, and shortened survival. Constitutive activation of the janus kinase/signal transducer and activator of transcription (...

Descripción completa

Detalles Bibliográficos
Autores principales: Talpaz, Moshe, Kiladjian, Jean-Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787977/
https://www.ncbi.nlm.nih.gov/pubmed/32647323
http://dx.doi.org/10.1038/s41375-020-0954-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787977/
https://www.ncbi.nlm.nih.gov/pubmed/32647323
http://dx.doi.org/10.1038/s41375-020-0954-2

Ejemplares similares